Northwest Bioth New (NWBO)

0.57 -0.13 (-18.57%)

After market: 0.53 -0.04 (-7.02%)

Technical Analysis

Fundamental Analysis

Analyst Ratings

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

Northwest Bioth New

NASDAQ:NWBO (12/16/2016, 7:10:00 PM)

After market: 0.53 -0.04 (-7.02%)

0.57

-0.13 (-18.57%)

Chartmill TA Rating

Chartmill Setup Rating

Sector

GICS SectorN/A

GICS IndustryN/A

Chartmill FA Rating

Valuation

Growth

Profitability

Health

Dividend

Overview

Earnings (Last)

Earnings (Next)

Ins Owners

Inst Owners

Market Cap109.33M

Shares

PEN/A

Fwd PEN/A

Dividend Yield0%

Analysts

IPO

Stock Screener Links

Nasdaq Stock Screener

Find more stocks on Nasdaq

USA Stock Screener

Find more stocks on the USA

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Company Profile

Northwest Biotherapeutics, Inc. is a biotechnology company focused on discovering, developing, and commercializing immunotherapy products that safely generate and enhance immune system responses to treat cancer.

Company Info

Northwest Bioth New

4800 MONTGOMERY LANE SUITE 800

BETHESDA MD 20814

P: 240-497-9024

CEO: Linda F. Powers

NWBO News

2 months ago - Northwest BiotherapeuticsNorthwest Biotherapeutics Appoints Seasoned Business Executive and Investor To Its Board of Directors

/PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor...

2 months ago - AB Newswire12 OTC Stocks to Watch: Clean Vision Corporation (OTCQB: CLNV), NaturalShrimp Inc (OTCQB: SHMP), Northwest Biotherapeutics, Inc. (OTCQB: NWBO), and More

3 months ago - Northwest BiotherapeuticsNorthwest Biotherapeutics Moves From Optimization of Flaskworks Prototype to Fabrication of GMP-Compliant Units For Installation, Validation and Final Testing Prior to Regulatory Certification

/PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor...

5 months ago - Northwest BiotherapeuticsNorthwest Biotherapeutics Announces That A Marketing Authorization Application Has Been Submitted To The UK MHRA For DCVax®-L For Glioblastoma

/PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor...

6 months ago - Northwest BiotherapeuticsNorthwest Biotherapeutics Provides Update On Final Preparations For Marketing Authorization Application

/PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor...

7 months ago - Northwest BiotherapeuticsNorthwest Biotherapeutics Provides Update On Near Term Plans For Submission of Marketing Authorization Application

/PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor...